{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T14:12:20Z","timestamp":1770991940022,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Adv Therapy"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1007\/s12325-009-0055-0","type":"journal-article","created":{"date-parts":[[2009,8,8]],"date-time":"2009-08-08T02:50:59Z","timestamp":1249699859000},"page":"739-748","source":"Crossref","is-referenced-by-count":40,"title":["Using oral ziprasidone effectively: the food effect and dose-response"],"prefix":"10.1007","volume":"26","author":[{"given":"Leslie","family":"Citrome","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,8,8]]},"reference":[{"key":"55_CR1","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1527-3458.2007.00008.x","volume":"13","author":"W.M. Greenberg","year":"2007","unstructured":"Greenberg WM, Citrome L. Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials. CNS Drug Rev. 2007;13:137\u2013177.","journal-title":"CNS Drug Rev"},{"key":"55_CR2","unstructured":"Pfizer, Inc. US Geodon (ziprasidone HCl) and Geodon (ziprasidone mesylate) for injection, LAB-0272-3.0 [package insert]. June 2008. Available at: www.pfizer.com\/files\/products\/uspi_geodon.pdf. Accessed June 1, 2009."},{"key":"55_CR3","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2165\/00023210-200317060-00004","volume":"17","author":"D. Taylor","year":"2003","unstructured":"Taylor D. Ziprasidone in the management of schizophrenia. CNS Drugs. 2003;17:423\u2013430.","journal-title":"CNS Drugs"},{"key":"55_CR4","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archpsyc.60.6.553","volume":"60","author":"J.M. Davis","year":"2003","unstructured":"Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003;60:553\u2013564.","journal-title":"Arch Gen Psychiatry"},{"key":"55_CR5","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1176\/appi.ajp.2008.08030368","volume":"166","author":"S. Leucht","year":"2009","unstructured":"Leucht S, Komossa K, Rummel-Kluge C, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry. 2009;166:152\u2013163.","journal-title":"Am J Psychiatry"},{"key":"55_CR6","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1517\/14656560903061309","volume":"10","author":"J. Volavka","year":"2009","unstructured":"Volavka J, Citrome L. Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making. Expert Opin Pharmacother. 2009;10:1917\u20131928.","journal-title":"Expert Opin Pharmacother"},{"key":"55_CR7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/j.1875-9114.1998.tb03820.x","volume":"18","author":"B.A. Hamelin","year":"1998","unstructured":"Hamelin BA, Allard S, Laplante L, et al. The effect of timing of a standard meal on the pharmacokinetics and pharmacodynamics of the novel atypical antipsychotic agent ziprasidone. Pharmacotherapy. 1998;18:9\u201315.","journal-title":"Pharmacotherapy"},{"key":"55_CR8","first-page":"58","volume":"40","author":"J.J. Miceli","year":"2007","unstructured":"Miceli JJ, Glue P, Alderman J, Wilner K. The effect of food on the absorption of oral ziprasidone. Psychopharmacol Bull. 2007;40:58\u201368.","journal-title":"Psychopharmacol Bull"},{"key":"55_CR9","doi-asserted-by":"crossref","first-page":"58","DOI":"10.4088\/JCP.08m04104","volume":"70","author":"K. Gandelman","year":"2009","unstructured":"Gandelman K, Alderman JA, Glue P, et al. The impact of calories and fat content of meals on oral ziprasidone absorption: a randomized, open-label, cross-over trial. J Clin Psychiatry. 2009;70:58\u201362.","journal-title":"J Clin Psychiatry"},{"key":"55_CR10","volume-title":"Solutions for Wellness","author":"B. Vreeland","year":"2008","unstructured":"Vreeland B, Toto AM, Sakowitz M. Solutions for Wellness. 3rd edition. Indianapolis, IN: Eli Lilly and Co; 2008.","edition":"3"},{"key":"55_CR11","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1097\/FTD.0b013e31818ac8ba","volume":"30","author":"M.D. Cherm\u00e1","year":"2008","unstructured":"Cherm\u00e1 MD, Reis M, H\u00e4gg S, Ahlner J, Bengtsson F. Therapeutic drug monitoring of ziprasidone in a clinical treatment setting. Ther Drug Monit. 2008;30:682\u2013688.","journal-title":"Ther Drug Monit"},{"key":"55_CR12","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.schres.2008.11.017","volume":"108","author":"L. Citrome","year":"2009","unstructured":"Citrome L, Reist C, Palmer L, et al. Dose trends for second-generation antipsychotic treatment of schizophrenia and bipolar disorder. Schizophr Res. 2009;108:238\u2013244.","journal-title":"Schizophr Res"},{"key":"55_CR13","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/01.jcp.0000169623.30196.b9","volume":"25","author":"L. Citrome","year":"2005","unstructured":"Citrome L, Jaffe A, Levine J. Dosing of second-generation antipsychotic medication in a state hospital system. J Clin Psychopharmacol. 2005;25:388\u2013391.","journal-title":"J Clin Psychopharmacol"},{"key":"55_CR14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1176\/ps.2007.58.1.11","volume":"58","author":"L. Citrome","year":"2007","unstructured":"Citrome L, Jaffe A, Levine J. The ups and downs of dosing second-generation antipsychotics. Psychiatr Serv. 2007;58:11.","journal-title":"Psychiatr Serv"},{"key":"55_CR15","doi-asserted-by":"crossref","first-page":"975","DOI":"10.4088\/JCP.08m04531","volume":"70","author":"L. Citrome","year":"2009","unstructured":"Citrome L, Jaffe A, Levine J. How dosing of ziprasidone in a state hospital system differs from product labeling. J Clin Psychiatry. 2009;70:975\u2013982.","journal-title":"J Clin Psychiatry"},{"key":"55_CR16","unstructured":"Citrome L, Reist C, Palmer L, et al. Impact of real-world ziprasidone dosing on treatment discontinuation rates in subjects with schizophrenia or bipolar disorder. Poster presentation NR6-105 presented at: 161st Annual Meeting of the American Psychiatric Association; May 3\u20138, 2008; Washington, DC."},{"key":"55_CR17","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.schres.2006.01.013","volume":"83","author":"C.D. Mullins","year":"2006","unstructured":"Mullins CD, Shaya FT, Zito JM, Obeidat N, Naradzay J, Harrison DJ. Effect of initial ziprasidone dose on treatment persistence in schizophrenia. Schizophr Res. 2006;83:277\u2013284.","journal-title":"Schizophr Res"},{"key":"55_CR18","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.schres.2006.01.009","volume":"83","author":"A.T. Joyce","year":"2006","unstructured":"Joyce AT, Harrison DJ, Loebel AD, Carter CT, Ollendorf DA. Effect of initial ziprasidone dose on length of therapy in schizophrenia. Schizophr Res. 2006;83:285\u2013292.","journal-title":"Schizophr Res"},{"key":"55_CR19","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.schres.2009.03.009","volume":"111","author":"L. Citrome","year":"2009","unstructured":"Citrome L, Yang R, Glue P, Karayal ON. Effect of ziprasidone dose on all-cause discontinuation rates in acute schizophrenia and schizoaffective disorder: a post-hoc analysis of 4 fixed-dose randomized clinical trials. Schizophr Res. 2009;111:39\u201345.","journal-title":"Schizophr Res"},{"key":"55_CR20","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/01.jcp.0000117422.05703.ae","volume":"24","author":"J.M. Davis","year":"2004","unstructured":"Davis JM, Chen N. Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol. 2004;24:192\u2013208.","journal-title":"J Clin Psychopharmacol"},{"key":"55_CR21","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1176\/appi.ajp.161.5.818","volume":"161","author":"D. Mamo","year":"2004","unstructured":"Mamo D, Kapur S, Shammi CM, et al. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry. 2004;161:818\u2013825.","journal-title":"Am J Psychiatry"},{"key":"55_CR22","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S0006-3223(01)01251-3","volume":"50","author":"S. Kapur","year":"2001","unstructured":"Kapur S, Remington G. Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry. 2001;50:873\u2013883.","journal-title":"Biol Psychiatry"},{"key":"55_CR23","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2165\/00023210-200822010-00005","volume":"22","author":"L. Citrome","year":"2008","unstructured":"Citrome L. Quetiapine: dose-response relationship in schizophrenia. CNS Drugs. 2008;22:69\u201372.","journal-title":"CNS Drugs"},{"key":"55_CR24","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/01.jcp.0000095347.32154.08","volume":"23","author":"P.J. Weiden","year":"2003","unstructured":"Weiden PJ, Daniel DG, Simpson G, Romano SJ. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J Clin Psychopharmacol. 2003;23:595\u2013600.","journal-title":"J Clin Psychopharmacol"},{"key":"55_CR25","doi-asserted-by":"crossref","first-page":"580","DOI":"10.4088\/JCP.v64n0514","volume":"64","author":"P.J. Weiden","year":"2003","unstructured":"Weiden PJ, Simpson GM, Potkin SG, O\u2019sullivan RL. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. J Clin Psychiatry. 2003;64:580\u2013588.","journal-title":"J Clin Psychiatry"},{"key":"55_CR26","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1176\/ajp.2006.163.4.611","volume":"163","author":"T.S. Stroup","year":"2006","unstructured":"Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry. 2006;163:611\u2013622.","journal-title":"Am J Psychiatry"},{"key":"55_CR27","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"J.A. Lieberman","year":"2005","unstructured":"Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209\u20131223.","journal-title":"N Engl J Med"},{"key":"55_CR28","first-page":"12","volume":"68suppl.12","author":"L. Citrome","year":"2007","unstructured":"Citrome L. The effectiveness criterion: balancing efficacy against the risks of weight gain. J Clin Psychiatry. 2007;68(suppl. 12):12\u201317.","journal-title":"J Clin Psychiatry"},{"key":"55_CR29","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/00131746-200203000-00004","volume":"8","author":"P.J. Weiden","year":"2002","unstructured":"Weiden PJ, Iqbal N, Mendelowitz AJ, Tandon R, Zimbroff DL, Ross R. Best clinical practice with ziprasidone: update after one year of experience. J Psychiatr Pract. 2002;8:81\u201397.","journal-title":"J Psychiatr Pract"},{"key":"55_CR30","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.312.7023.71","volume":"312","author":"D.L. Sackett","year":"1996","unstructured":"Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn\u2019t. BMJ. 1996;312:71\u201372.","journal-title":"BMJ"},{"key":"55_CR31","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1742-1241.2009.02014.x","volume":"63","author":"L. Citrome","year":"2009","unstructured":"Citrome L, Ketter TA. Teaching the philosophy and tools of evidence-based medicine: misunderstandings and solutions. Int J Clin Pract. 2009;63:353\u2013359.","journal-title":"Int J Clin Pract"},{"key":"55_CR32","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.4088\/JCP.v68n1207","volume":"68","author":"L. Citrome","year":"2007","unstructured":"Citrome L. Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. J Clin Psychiatry. 2007;68:1876\u20131885.","journal-title":"J Clin Psychiatry"},{"key":"55_CR33","doi-asserted-by":"crossref","first-page":"933","DOI":"10.4088\/JCP.v61n1208","volume":"61","author":"S. Brook","year":"2000","unstructured":"Brook S, Lucey JV, Gunn KP. Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. J Clin Psychiatry. 2000;61:933\u2013941.","journal-title":"J Clin Psychiatry"},{"key":"55_CR34","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/s00213-004-2082-5","volume":"178","author":"S. Brook","year":"2005","unstructured":"Brook S, Walden J, Benattia I, Siu CO, Romano SJ. Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study. Psychopharmacology (Berl). 2005;178:514\u2013523.","journal-title":"Psychopharmacology (Berl)"},{"key":"55_CR35","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/00004850-200401000-00002","volume":"19","author":"D.G. Daniel","year":"2004","unstructured":"Daniel DG, Zimbroff DL, Swift RH, Harrigan EP. The tolerability of intramuscular ziprasidone and haloperidol treatment and the transition to oral therapy. Int Clin Psychopharmacol. 2004;19:9\u201315.","journal-title":"Int Clin Psychopharmacol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-009-0055-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-009-0055-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-009-0055-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T19:45:09Z","timestamp":1710531909000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-009-0055-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["55"],"URL":"https:\/\/doi.org\/10.1007\/s12325-009-0055-0","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8]]}}}